Eli Lilly Considers Acquisition of Abivax to Enhance Pipeline Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 07 Jan 26
Source: Fool
Abivax SA's stock rose by 6.77% as it crossed above the 5-day SMA, reflecting positive market conditions.
This surge is attributed to Eli Lilly's consideration of acquiring Abivax, which could enhance its pipeline with the promising drug obefazimod for ulcerative colitis treatment. The potential acquisition highlights Eli Lilly's strategy to strengthen its market position amid robust clinical trial results showing significant remission rates in phase 3 trials for obefazimod.
The implications of this potential acquisition could be substantial for both companies, as it may lead to enhanced growth opportunities for Eli Lilly and increased visibility for Abivax in the biotech sector.
Analyst Views on ABVX
Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is 153.88 USD with a low forecast of 131.00 USD and a high forecast of 176.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 113.980
Low
131.00
Averages
153.88
High
176.00
Current: 113.980
Low
131.00
Averages
153.88
High
176.00
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
